Skip to main content
. 2021 Feb 4;11:626820. doi: 10.3389/fimmu.2020.626820

Figure 2.

Figure 2

Soluble CD52 levels are elevated in SLE plasma and correlate with disease severity. (A) Plasma CD52 concentrations in HC (n = 18) and SLE patients (n = 22) as determined by ELISA. Differences between groups determined by two-tailed Mann-Whitney test. (B) Correlation between plasma CD52 and C4 levels in SLE (n = 37). Correlations were performed using Spearman’s two-tailed method. (C) Plasma CD52 levels in SLE patients with trace levels of C-reactive protein (<0.2 mg/dl; n = 15) or detectable levels (≥0.2 mg/dl; n = 16). Differences between groups determined by two-tailed Mann-Whitney test. (D, E) Correlations between plasma CD52 and (D) plasma IgG and (E) IgM levels among SLE patients (n = 40). Correlations performed using Spearman’s non-parametric two-tailed method. (F) Comparison of plasma CD52 levels in patients without any history of anti-dsDNA (n = 16) antibodies to those with a history of anti-dsDNA antibodies (n = 20). (G) Comparison of plasma CD52 levels in patients without a history of anti-RNP antibodies (n = 24) to patients with a history of anti-RNP antibodies (n = 13). (H) Comparison of plasma CD52 levels in patients with without any history of nephritis (n = 27) to those with active or previous diagnosis of lupus nephritis (n = 11). Two-tailed Mann-Whitney test used to compare differences between the groups. **p < 0.01, ****p < 0.0001. ns, not significant.